629 related articles for article (PubMed ID: 26615369)
21. Aspirin-exacerbated respiratory disease and current treatment modalities.
Sakalar EG; Muluk NB; Kar M; Cingi C
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737
[TBL] [Abstract][Full Text] [Related]
22. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs.
Campo P; Ayuso P; Salas M; Plaza MC; Cornejo-García JA; Doña I; Torres MJ; Blanca-López N; Canto G; Guéant JL; Sanak M; Blanca M
Allergy; 2013 Aug; 68(8):1001-7. PubMed ID: 23889565
[TBL] [Abstract][Full Text] [Related]
23. Management of Aspirin-Exacerbated Respiratory Disease: What Does the Future Hold?
O'Brien EK; Jerschow E; Divekar RD
Otolaryngol Clin North Am; 2024 Apr; 57(2):265-278. PubMed ID: 37833102
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma.
Bochenek G; Stachura T; Szafraniec K; Plutecka H; Sanak M; Nizankowska-Mogilnicka E; Sladek K
J Allergy Clin Immunol Pract; 2018; 6(2):528-535. PubMed ID: 28888846
[TBL] [Abstract][Full Text] [Related]
25. Aspirin-Exacerbated Respiratory Disease.
Walgama ES; Hwang PH
Otolaryngol Clin North Am; 2017 Feb; 50(1):83-94. PubMed ID: 27888917
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
Perić A; Gaćeša D; Cvetković G; Vojvodić D
Immun Inflamm Dis; 2023 Feb; 11(2):e791. PubMed ID: 36840483
[TBL] [Abstract][Full Text] [Related]
27. Dysregulated survivin expression in nasal polyps of individuals with aspirin exacerbated respiratory disease.
Fruth K; Schramek E; Docter D; Haxel BR; Schneider A; Mann WJ; Brieger J
Am J Rhinol Allergy; 2012; 26(5):380-4. PubMed ID: 23168152
[TBL] [Abstract][Full Text] [Related]
28. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease.
Aksu K; Kurt E; Alatas Ö; Gülbas Z
Allergy Asthma Proc; 2014; 35(2):148-55. PubMed ID: 24717792
[TBL] [Abstract][Full Text] [Related]
29. Aspirin challenge in patients with chronic rhinosinusitis with polyps correlates with local and systemic inflammatory markers.
Forer B; Landsberg R; Kivity S
Am J Rhinol Allergy; 2013; 27(6):e170-3. PubMed ID: 24274209
[TBL] [Abstract][Full Text] [Related]
30. Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.
Edward JA; Sanyal M; Ramakrishnan VR; Le W; Nguyen AL; Kingdom TT; Hwang PH; Nayak JV
Int Forum Allergy Rhinol; 2013 Nov; 3(11):866-76. PubMed ID: 24106221
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Kamide Y; Nakamura Y; Hamada Y; Tomita Y; Sekiya K; Tsuburai T; Izuhara K; Wakahara K; Hashimoto N; Hasegawa Y; Taniguchi M
Am J Respir Crit Care Med; 2020 Jun; 201(12):1488-1498. PubMed ID: 32142372
[No Abstract] [Full Text] [Related]
32. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
Berges-Gimeno MP; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2002 Nov; 89(5):474-8. PubMed ID: 12452205
[TBL] [Abstract][Full Text] [Related]
33. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Buchheit KM; Sohail A; Hacker J; Maurer R; Gakpo D; Bensko JC; Taliaferro F; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2022 Aug; 150(2):415-424. PubMed ID: 35460728
[TBL] [Abstract][Full Text] [Related]
34. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
35. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
36. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.
Stevenson DD; Mehra PK; White AA; Gupta S; Woessner KM; Simon RA
J Allergy Clin Immunol; 2005 Oct; 116(4):755-60. PubMed ID: 16210047
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.
Scott WC; Cahill KN; Milne GL; Li P; Sheng Q; Huang LC; Dennis S; Snyder J; Bauer AM; Chandra RK; Chowdhury NI; Turner JH
J Allergy Clin Immunol; 2021 Apr; 147(4):1318-1328.e5. PubMed ID: 33189729
[TBL] [Abstract][Full Text] [Related]
38. Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.
Jerschow E; Ren Z; Hudes G; Sanak M; Morales E; Schuster V; Spivack SD; Rosenstreich D
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):321-328.e1. PubMed ID: 26822279
[TBL] [Abstract][Full Text] [Related]
39. Prostaglandin E
Mastalerz L; Tyrak KE; Ignacak M; Konduracka E; Mejza F; Ćmiel A; Buczek M; Kot A; Oleś K; Sanak M
Allergy; 2019 May; 74(5):922-932. PubMed ID: 30446997
[TBL] [Abstract][Full Text] [Related]
40. Current complications and treatment of aspirin-exacerbated respiratory disease.
Cook KA; Stevenson DD
Expert Rev Respir Med; 2016 Dec; 10(12):1305-1316. PubMed ID: 27817219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
